Michael Schmohl

997 citations

18 papers · 710 indexed · h-index 11

Impact in

Internal Medicine top 1%
- Venous Thromboembolism Diagnosis and Management
Cardiology and Cardiovascular Medicine top 5%
- Atrial Fibrillation Management and Outcomes
- Cardiac Arrhythmias and Treatments
- Antiplatelet Therapy and Cardiovascular Diseases
- Acute Myocardial Infarction Research

Papers in ⓘ

Cardiology and Cardiovascular Medicine 8
- Atrial Fibrillation Management and Outcomes 8
- Acute Myocardial Infarction Research 3
Immunology 6
- interferon and immune responses 5

Co-authors: Joachim Stangier (8 shared papers)Viktoria Moschetti (7 shared papers)Paul Reilly (7 shared papers)Stephan Glund (6 shared papers)Benjamin Lang (5 shared papers)Stephen H. Norris (5 shared papers)Steven Ramael (4 shared papers)Joanne van Ryn (3 shared papers)
Journals: Thrombosis and Haemostasis (2 papers)Research and Practice in Thrombosis and Haemostasis (1 paper)Future Oncology (1 paper)PROTEOMICS (1 paper)Circulation (1 paper)
Partner nations: Germany United States United Kingdom

In The Last Decade

Michael Schmohl

18 papers receiving 686 citations

Peers

Countries citing papers authored by Michael Schmohl

Since Specialization

Citations

This map shows the geographic impact of Michael Schmohl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Schmohl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Schmohl more than expected).

Fields of papers citing papers by Michael Schmohl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Schmohl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Schmohl. The network helps show where Michael Schmohl may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael Schmohl, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael Schmohl Line = papers co-authored together Michael Schmohl links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work
1	Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial The Lancet ·Stephan Glund, Joachim Stangier, Michael Schmohl, Dietmar Ganßer, Stephen H. Norris, Joanne van Ryn, Benjamin Lang, Steven Ramael, Viktoria Moschetti, Fredrik Gruenenfelder, Paul Reilly, Jörg Kreuzer	2015	237
2	A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran Thrombosis and Haemostasis ·Viktoria Moschetti, Stephen H. Norris, Joachim Stangier, Michael Schmohl, Joanne van Ryn, Benjamin Lang, Steven Ramael, Paul Reilly, Stephan Glund	2015	183
3	Idarucizumab, a Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Elderly and Renally Impaired Subjects Blood ·Stephan Glund, Joachim Stangier, Michael Schmohl, Viktoria Moschetti, Wouter Haazen, Marina De Smet, Dietmar Ganßer, Stephen H. Norris, Benjamin Lang, Paul Reilly	2014	59
4	Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study Clinical Pharmacokinetics ·Stephan Glund, Joachim Stangier, Joanne van Ryn, Michael Schmohl, Viktoria Moschetti, Wouter Haazen, Marina De Smet, Dietmar Ganßer, Stephen H. Norris, Benjamin Lang, Paul Reilly, Jörg Kreuzer	2016	58
5	Abstract 17765: A Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Healthy Male Volunteers Circulation ·Stephan Glund, Joachim Stangier, Michael Schmohl, Marina De Smet, Dietmar Ganßer, Benjamin Lang, Viktoria Moschetti, Steven Ramael, Paul Reilly	2013	41
6	Superficial Wound Swabbing Diabetes Care ·Michael Schmohl, Stefan Beckert, Thomas Joos, Alfred Königsrainer, Nicole Schneiderhan‐Marra, Markus Löffler	2012	27
7	Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers Thrombosis and Haemostasis ·Michael Schmohl, Stephan Glund, Akiko Harada, Susumu Imazu, Marina De Smet, Viktoria Moschetti, Steven Ramael, Ippei Ikushima, Fredrik Grünenfelder, Paul Reilly, Joachim Stangier	2016	23
8	Immune Profiling in Blood Identifies sTNF-R1 Performing Comparably Well as Biomarker Panels for Classification of Alzheimer's Disease Patients Journal of Alzheimer s Disease ·Christoph Laske, Michael Schmohl, Thomas Leyhe, Elke Stransky, Walter Maetzler, Daniela Berg, Andreas J. Fallgatter, Thomas Joos, Janko Dietzsch	2013	16
9	Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study Research and Practice in Thrombosis and Haemostasis ·Masahiro Yasaka, Ippei Ikushima, Akiko Harada, Susumu Imazu, Atsushi Taniguchi, Stephen H. Norris, Dietmar Ganßer, Joachim Stangier, Michael Schmohl, Paul Reilly	2017	13
10	Characterization of immunologically active drugs in a novel organotypic co-culture model of the human gut and whole blood International Immunopharmacology ·Michael Schmohl, Nicole Schneiderhan‐Marra, Nadja Baur, Kathrin Hefner, Michael Blum, Gerburg M. Stein, Thomas Joos, Manfred Schmolz	2012	11
11	Measurement of dabigatran plasma concentrations by calibrated thrombin clotting time in comparison to LC-MS/MS in human volunteers on dialysis Thrombosis Research ·Michael Schmohl, Dietmar Ganßer, Viktoria Moschetti, Joachim Stangier	2015	11
12	Abstract CT217: Phase I, first-in-human trial evaluating BI 1387446 (STING agonist) alone and in combination with ezabenlimab (BI 754091; anti-PD-1) in solid tumors Cancer Research ·Kevin J. Harrington, Eileen E. Parkes, Jared Weiss, M. Ingham, Andrés Cervantes, Emiliano Calvo, Ute Klinkhardt, Patricia Sikken, Michael Schmohl, Elena Garralda	2021	8
13	1030P Phase I, first-in-human trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenlimab in solid tumors Annals of Oncology ·Emiliano Calvo, Elena Garralda, Guzmán Alonso, Valentina Gambardella, E.E. Parkes, J N Thompson, Robert Latek, Patricia Sikken, Michael Schmohl, Kevin J. Harrington	2023	7
14	Protein–protein‐interactions in a multiplexed, miniaturized format a functional analysis of Rho GTPase activation and inhibition PROTEOMICS ·Michael Schmohl, Stefanie Rimmele, Oliver Pötz, Yoel Kloog, Peter Gierschik, Thomas Joos, Nicole Schneiderhan‐Marra	2010	6
15	408 Phase I, first-in-human trial evaluating BI 1387446 (stimulator of interferon genes [STING] agonist) alone and combined with BI 754091 (anti-programmed cell death [PD]-1) in solid tumors Regular and Young Investigator Award Abstracts ·Kevin J. Harrington, Eileen E. Parkes, Jared Weiss, M. Ingham, Andrés Cervantes, Emiliano Calvo, Matthew J. Riese, Ute Klinkhardt, Patricia Sikken, Michael Schmohl, Elena Garralda	2020	4
16	Functional Analysis of Rho GTPase Activation and Inhibition in a Bead-Based Miniaturized Format Methods in molecular biology ·Michael Schmohl, Stefanie Rimmele, Peter Gierschik, Thomas Joos, Nicole Schneiderhan‐Marra	2011	2
17	Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors Future Oncology ·Kevin J. Harrington, Shigehisa Kitano, Valentina Gambardella, Eileen E. Parkes, Irene Moreno, Guzmán Alonso, Toshihiko Doi, David Berz, Martin Gutierrez, Natalia Fernández, Michael Schmohl, José Barrueco, Patricia LoRusso	2025	2
18	626 Trial in progress: an intravenously administered second-generation STING agonist, BI 1703880 with a novel lead-in design in combination with ezabenlimab Regular and Young Investigator Award Abstracts ·Kevin J. Harrington, Elizabeth M. Dowling, Robert Latek, Michael Schmohl, Patricia LoRusso	2022	2

About Michael Schmohl

Michael Schmohl is a scholar working on Cardiology and Cardiovascular Medicine, Immunology, Molecular Biology, Internal Medicine and Oncology, having authored 18 papers that have together received 710 indexed citations. Recurring topics across this work include Atrial Fibrillation Management and Outcomes (8 papers), interferon and immune responses (5 papers), Venous Thromboembolism Diagnosis and Management (4 papers), Acute Myocardial Infarction Research (3 papers), Cancer Immunotherapy and Biomarkers (2 papers), Cancer Research and Treatments (2 papers), Protein Kinase Regulation and GTPase Signaling (2 papers) and Blood Coagulation and Thrombosis Mechanisms (2 papers). The work is most often cited by research in Internal Medicine (400 citations), Cardiology and Cardiovascular Medicine (563 citations), Hematology (61 citations), Biological Psychiatry (9 citations) and Neurology (49 citations). Michael Schmohl has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Joachim Stangier, Viktoria Moschetti, Paul Reilly, Stephan Glund, Benjamin Lang, Stephen H. Norris, Steven Ramael, Joanne van Ryn, Dietmar Ganßer and Jörg Kreuzer. Their work appears in journals such as Thrombosis and Haemostasis, Research and Practice in Thrombosis and Haemostasis, Future Oncology, PROTEOMICS and Circulation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact